Actively Recruiting
Study to Discover New Biomarkers for Biliary Tract Cancer Including Cholangiocarcinoma and Gallbladder Cancer to Improve Diagnosis, Treatment, and Prognosis
Led by Herlev and Gentofte Hospital · Updated on 2022-01-11
500
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Biliary tract cancer BTC, including cholangiocarcinoma and gallbladder cancer, is a serious disease with a poor prognosis and limited treatment options. This research aims to find new biomarkers that can help diagnose BTC earlier, predict treatment outcomes, and improve understanding of the disease. Currently, only one biomarker, CA 19-9, is used but has limited value for predicting diagnosis or prognosis. This observational study collects biological samples such as blood and tissue from patients diagnosed with BTC who are receiving standard or protocolized treatment. Samples are taken before surgery or chemotherapy, during treatment, and at regular follow-up visits about every three months. Clinical data including patient demographics, disease details, treatments, blood tests, and outcomes are also collected and analyzed. Participants will be followed until death, with regular monitoring of disease progression and survival. Researchers will analyze various molecules like DNA, RNA, proteins, and metabolites to identify useful biomarkers. The main outcomes measured are diagnostic accuracy and overall survival, along with progression-free survival and adverse events, to better understand BTC and improve patient care.
CONDITIONS
Brief Title
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here